万春医药上涨3.41%，报2.12美元/股，总市值8547.06万美元

Core Insights - BeyondSpring Pharmaceuticals (BYSI) experienced a stock price increase of 3.41% on August 6, reaching $2.12 per share, with a total market capitalization of $85.47 million [1] - As of June 30, 2024, the company reported total revenue of $1.00 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.26 million, showing a 42.91% increase in losses compared to the previous year [1] - The company is set to disclose its fiscal year 2024 annual report on May 5, with the actual release date subject to company announcements [1] Company Overview - BeyondSpring Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [1] - Founded in 2013 and headquartered in the United States, the company aims to leverage its academic and business expertise in cancer treatment to transform the current landscape of cancer therapy [1] - The primary project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers due to its biochemical activities [1] Business Model and Research Focus - The company employs an innovative and highly scalable business model that integrates resources from both the U.S. and China to efficiently and cost-effectively achieve drug approval and development [1] - Key research areas include non-small cell lung cancer, prevention of neutropenia, and the combination of Plinabulin with PD-1 monoclonal antibodies [1]